Menopause is usually the permanent termination of physiological menstruation or permanent loss of ovarian estrogen synthesis due to breast cancer treatment. The criteria for menopause are as follows: post bilateral oophorectomy; age ≥ 60 years; age < 60 years and menopause for more than 1 year in the absence of chemotherapy and treatment with triamcinolone, toremifene and ovarian function suppression, while blood FSH and estradiol levels are in the postmenopausal range; while menopausal patients taking triamcinolone, toremifene and age < 60 years must have continuous testing of blood FSH and estradiol levels in the post-menopausal range. It is also important to note that women who are receiving LH-RH agonists or antagonists cannot be determined to be menopausal. In women who were not menopausal prior to adjuvant chemotherapy, menopause cannot be used as a basis for determining menopause because although the patient may stop ovulating or have no menstruation after chemotherapy, ovarian function may still be normal or may recover. In women with chemotherapy-induced menopause, if an aromatase inhibitor is considered as endocrine therapy, effective ovarian suppression (complete bilateral ovariectomy or pharmacological suppression) needs to be considered or the patient's postmenopausal status has been confirmed by serial monitoring of FSH/ or estradiol levels.